IC7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables DemandICU Medical’s infusion and vascular-access portfolio combines capital equipment with routinely consumed sets, catheters and connectors. This recurring component can support repeat hospital purchasing, improve revenue visibility, and make the business less dependent on one-time pump sales over the next several quarters.
Organic And Core Business GrowthOrganic growth and record performance in both pumps and consumables indicate that demand is broadening across core product families rather than relying on a single product. Continued adoption can strengthen scale, support operating leverage, and reinforce ICU Medical’s position in hospital infusion therapy.
Improving Cash Flow And GuidanceStrong free cash flow is enabling debt reduction while management raises its full-year earnings outlook. If this conversion continues, ICU Medical can improve financial flexibility, move toward its roughly 2x leverage target, and fund operations without relying as heavily on additional borrowing.
Bears Say
Thin And Volatile ProfitabilityThe recent earnings rebound has not yet demonstrated durable profitability because net and operating margins remain modest and prior-year losses were significant. This volatility limits confidence in normalized earnings power and leaves less operating cushion if demand, product mix, or costs deteriorate.
Persistent Tariff ExpenseTariffs represent an ongoing cost burden rather than a one-quarter issue, with management estimating tens of millions of dollars in annual expense. Unless offset by pricing or efficiency, this pressure can restrain gross-margin improvement, reduce cash generation, and limit the benefit of revenue growth.
Vital Care Weakness And JV ImpactWeak Vital Care performance and limited expected JV contribution create a continuing drag on the company’s growth mix. The contrast with stronger core businesses may constrain consolidated expansion and makes the earnings recovery more dependent on sustained execution in infusion systems and consumables.
ICU Medical News
IC7 FAQ
What was Icu Medical’s price range in the past 12 months?
Currently, no data Available
What is Icu Medical’s market cap?
Icu Medical’s market cap is CHF3.39B.
When is Icu Medical’s upcoming earnings report date?
Icu Medical’s upcoming earnings report date is Nov 05, 2026 which is in 7 days.
How were Icu Medical’s earnings last quarter?
Icu Medical released its earnings results on Aug 06, 2026. The company reported CHF1.966 earnings per share for the quarter, beating the consensus estimate of CHF1.588 by CHF0.378.
Is Icu Medical overvalued?
According to Wall Street analysts Icu Medical’s price is currently Undervalued.
Does Icu Medical pay dividends?
Icu Medical does not currently pay dividends.
What is Icu Medical’s EPS estimate?
Icu Medical’s EPS estimate is 1.77.
How many shares outstanding does Icu Medical have?
Icu Medical has 25,007,038 shares outstanding.
What happened to Icu Medical’s price movement after its last earnings report?
Icu Medical reported an EPS of CHF1.966 in its last earnings report, beating expectations of CHF1.588. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Icu Medical?
Currently, no hedge funds are holding shares in CH:IC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ICU Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF162.20 (― Upside)
CHF162.20 (― Upside)
Blogger Sentiment
Bullish
CH:IC7 Sentiment 60%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth CHF2.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.78%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Icu Medical
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
IC7 Company Deck
IC7 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a positive operational and financial trajectory: record revenues in key businesses, margin expansion, raised full-year guidance, and strong free cash flow enabled a $50M debt paydown and progress toward a ~2x leverage target. Headwinds remain — notably tariffs, currency impacts, restructuring charges, and a weakened Vital Care reported performance due to JV deconsolidation — and there is some timing uncertainty around regulatory resubmissions and project phasing. On balance, the company emphasized momentum and achievable margin/cash goals despite macro and one-time pressures.View all CH:IC7 earnings summariesIC7 Stock 12 Month Forecast
Average Price Target
―AngioDynamics
―
Baxter International
―
Becton Dickinson
―
Merit Medical Systems
―
Teleflex
―